The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of FOLFIRINOX with PEG-G-CSF for unresectable/recurrent pancreatic cancer.
 
Ichiro Moriyama
Honoraria - Lilly Japan; Olympus Medical Systems; Taiho Pharmaceutical
 
Hiroki Sonoyama
No Relationships to Disclose
 
Yasunari Kawabata
No Relationships to Disclose
 
Fumiyoshi Ikejiri
No Relationships to Disclose
 
Masaya Inoue
No Relationships to Disclose
 
Fumimasa Takahashi
No Relationships to Disclose
 
Shinichiro Matsuda
No Relationships to Disclose
 
Norimi Ugata
No Relationships to Disclose
 
Yasumasa Shimasaki
No Relationships to Disclose
 
Ayumi Fujimoto
No Relationships to Disclose
 
Yusuke Okada
No Relationships to Disclose
 
Shunsuke Ito
No Relationships to Disclose
 
Takahiro Okada
No Relationships to Disclose
 
Yumi Jo
No Relationships to Disclose
 
Tsutomu Takahashi
Honoraria - Bristol-Myers Squibb Japan; Celgene; Kyowa Hakko Kirin
 
Takaaki Miyake
Honoraria - Celgene; Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical; Pfizer; Takeda
 
Tatsuo Kodama
No Relationships to Disclose
 
Ritsuro Suzuki
Honoraria - Bristol-Myers Squibb; Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Novartis; Ono Pharmaceutical; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Gilead Sciences; Mundipharma
 
Yoshitsugu Tajima
No Relationships to Disclose
 
Junji Suzumiya
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Nippon Shinyaku; Ono Pharmaceutical; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Celgene; Janssen Oncology; Zenyaku Kogyo
Speakers' Bureau - Chugai Pharma; Eisai; Janssen Oncology; Takeda
Research Funding - Astellas Pharma (Inst); Celltrion (Inst); Chugai Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Sumitomo Dainippon (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)